|
KMID : 1144320220540040781
|
|
감염과 화학요법
2022 Volume.54 No. 4 p.781 ~ p.786
|
|
|
Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
|
|
Kwak Yee-Gyung
Song Je-Eun
Kang Ji-Eun
Kang Ji-Yeon
Kang Hyung-Koo
Koo Hyeon-Kyoung
Park Hye-Kyeong
Choi Sang-Bong
Lee Hyuk-Pyo
Lee Myung-Jin
Kim Baek-Nam
|
|
|
Abstract
|
|
|
|
Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.
|
|
|
KEYWORD
|
|
|
COVID-19, Regdanvimab, Delta variant
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|